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Abstract: Bacterial multidrug resistance is becoming a growing problem for public health, due to
the development and spreading of bacterial strains resistant to antimicrobials. In this study, the
antibacterial and multidrug resistance reversing activity of a series of seleno-carbonyl compounds
has been evaluated. The effects of eleven selenocompounds on bacterial growth were evaluated in
Staphylococcus aureus, methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Escherichia coli, and
Chlamydia trachomatis D. The combination effect of compounds with antibiotics was examined by the
minimum inhibitory concentration reduction assay. Their efflux pump (EP) inhibitory properties
were assessed using real-time fluorimetry. Relative expressions of EP and quorum-sensing genes
were studied by quantitative PCR. Results showed that a methylketone selenoester had remarkable
antibacterial activity against Gram-positive bacteria and potentiated the activity of oxacillin in MRSA.
Most of the selenocompounds showed significant anti-chlamydial effects. The selenoanhydride
and the diselenodiester were active inhibitors of the AcrAB-TolC system. Based on these results
it can be concluded that this group of selenocompounds can be attractive potential antibacterials
and EP inhibitors. The discovery of new derivatives with a significant antibacterial activity as novel
selenocompounds, is of high impact in the fight against resistant pathogens.
Keywords: selenocompounds; selenoesters; AcrAB-TolC efflux pump; Chlamydia trachomatis D;
Escherichia coli K-12 AG100; Staphylococcus aureus
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1. Introduction
Multidrug resistance is becoming a serious problem in the treatment of resistant bacterial infections.
The discovery of novel antibacterial or multidrug resistance reversing agents is extremely urgent as
soon we may lack effective drugs to treat bacterial infections caused by the arising superbugs resistant
to the majority of the clinically available antibiotics [1]. Selenium (Se)-containing molecules could be
possible alternatives in the development of a new approach to combat infections caused by multidrug
resistant (MDR) pathogens. Se is an important element in biological molecules in archea, bacteria, and
eukaryotes [2]. In humans, Se is an essential trace element and also has chemopreventive effects [3].
In this context, a few studies have reported that certain selenocompounds have shown an
interesting antibacterial activity. First, a series of selenides-bearing benzenesulfonamide moieties
has been found to strongly inhibit the carbonic anhydrases VchCAα and VchCAβ of Vibrio cholerae,
thus, exerting an inhibition on the growth and pathogenicity of this bacterium [4]. In addition, a
degraded selenide polysaccharide, extracted from Enteromorpha prolifera, has been found to show
antibacterial activity against Escherichia coli [5]. Additionally, a series of fused selenazolinium salts have
been shown to have a potent activity against ESKAPE pathogens, which are: vancomycin-resistant
Enterococci, methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and carbapenem-resistant Enterobacteriaceae. The majority of these
compounds have minimum inhibitory concentration (MIC) values below 1 µg/mL, in resistant bacterial
strains of MRSA, K. pneumoniae, A. baumanii, and P. aeruginosa [6]. This last work highlights the potential
applications of selenocompounds, in the treatment of infections caused by the MDR bacterial strains.
Our previous studies have demonstrated that the selenoanhydride 1 and selected selenoesters 2–11
(Table 1) have shown potent anticancer activity against ATP-Binding cassette sub-family B member 1
(ABCB1)-overexpressing MDR mouse T-lymphoma cells and MDR colon adenocarcinoma cells [7,8].
The ABC family of protein transporters also plays an important role in bacterial multidrug resistance [9].
Several members of the ABC family, e.g., MsrA in staphylococci [10,11] or Msr(D) in Streptococcus
pneumoniae [12], significantly contribute to the efflux of antibiotics, and are considered as attractive
protein targets in experimental chemotherapy. A major factor of bacterial and cancer drug resistance
is assigned to the MDR efflux transporter proteins, expelling toxic compounds and drugs out of the
cells. Based on the energy source of these pumps, the primary transporter derives their energy from
the hydrolysis of ATP (ABC-transporters) and secondary transporters use proton or ion gradients to
drive the extrusion of toxic compounds. Using selenocompounds, such as chemosensitizers, these
compounds have been shown to inhibit the ABCB1 in cancer cells [7,8], and based on these results,
our aim was to investigate the efflux pump inhibitory properties of these selenocompounds on the
representative bacterial efflux system AcrAB-TolC. RND (Resistance–Nodulation–Division) family
transporters are widespread, especially among Gram-negative bacteria, and catalyse the efflux of
antibiotics and biocides. This tripartite efflux system consists of an outer membrane channel and
periplasmic adaptor proteins, and the inner membrane transporter AcrB [13]. The MarR transcription
factor regulates resistance to diverse antibiotics, organic solvents and oxidative stress agents by
controlling the expression of efflux pumps (including AcrAB-TolC) through the repression of the
operon that encodes the transcriptional activator MarA. The antibiotic resistance arises when the MarR
protein is inactivated or the expression of marR genes is inhibited [14]. Although the expression of
AcrAB-TolC efflux pump is regulated at several levels, the MarR the AcrR also regulates it negatively,
meanwhile, the MarA, SoxS, and Rob are activators of this efflux pump [15]. In addition, the quorum
sensing (QS) regulators, such as SdiA could also affect the expression of AcrAB-TolC efflux pump in
E. coli, since AcrAB-TolC has been proposed to pump out QS signals [16].
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Table 1. Selenocompounds evaluated as antibacterial and as multidrug resistance reversing
agents—selenoanhydride (1) and selenoesters (2–11).
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Furthermore, coating surfaces with Se could reduce the bacterial attachment to prosthetic
devices [17], whereas sodium selenite exhibited ulcer healing and antibacterial activity against
Helicobacter pylori [18]. Various studies have highlighted the antimicrobial properties of elemental Se,
in the form of nanoparticles (SeNP) against S. aureus [19–22], Staphylococcus epidermidis, K. pneumoniae,
Bacillus subtilis [23], P. aeruginosa, E. coli, and A. baumannii [24]. Additionally, biogenic SeNPs,
synthesized by different non-pathogenic bacterial strains and stabilized with bacterial proteins, have
shown activity against pathogenic bacteria [25,26].
In addition, there is an emerging evidence that Chlamydia trachomatis is developing resistance to
antibiotics, as certain clinical isolates have shown single- or multidrug resistance [27,28]. Consequently,
the development of new antibacterials and multidrug resistance reversing compounds is required to
overcome this emerging problem. Although there are numerous studies that have investigated the
antibacterial activity of Se-containing (in)organic compounds and SeNPs, according to our knowledge,
no report has been described regarding anti-chlamydial activity of selenocompounds. Furthermore,
the selenocompounds found as anticancer agents and cancer efflux pump inhibitors have not yet been
tested on any bacterial strains.
Herein, we report the antibacterial effects of selenocompounds 1–11 on Gram-negative and
Gram-positive bacteria, such as E. coli, C. trachomatis D, Enterococcus faecalis, and S. aureus (including
ethicillin resistant strain, MRSA).
2. Results
2.1. Antibacterial Activity: Determination of the MIC
The ketone-containing selenoesters 9–11 showed a potent antibacterial activity against the
Gram-positive S. aureus ATCC 25923 and MRSA HEMSA 5. The methylketone selenoester 9 was
the most ctive agent with noteworthy MIC values in the low micromolar range (3.12 and 3.91 µM).
The tert-butylketone selenoesters 10 and 11 showed lower antibacterial activity than methylketone
selenoester 9, but was still significant (25 and 50 µM). The selenoanhydride 1 and the remaining
selenoesters 2–8 evaluated were inactive as their MIC were equal or above 100 µM. The selenoester 9
showed also significant antibacterial activity towards E. faecalis, but this Gram-positive strain was less
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sensitive to 9 than S. aureus and MRSA (MIC = 12.5 µM), and also was not sensitive to the rest of the
selenocompounds tested (MIC > 100 µM), (Table 2).
In contrast, none of the eleven Se derivatives demonstrated antibacterial effects against the two
Gram-negative strains evaluated in this study, which are the AcrAB-TolC-expressing E. coli AG100
and the AcrAB-TolC-deleted mutant E. coli AG100A. In these two strains, all compounds showed MIC
values above 100 µM (data not shown).
Table 2. Minimum inhibitory concentration (MICs) of the selenocompounds on the Gram-positive
bacteria. In bold—MIC values <10 µM.
Compounds
MIC (µM)
Staphylococcus aureus
ATCC 25923
Staphylococcus aureus
HEMSA 5
Enterococcus Faecalis
ATCC 29212
1 >100 >125 >100
2 100 >125 >100
3 100 >125 >100
4 100 >125 >100
5 >100 >125 >100
6 >100 >125 >100
7 100 125 >100
8 100 >125 >100
9 3.12 3.91 12.5
10 25 >125 >100
11 50 >125 >100
2.2. Enhancement of the Activity of Antibiotics
In order to determine if selenocompounds 1–11 enhance the activity of antibiotics, they were
tested in combination with antibiotics commonly used in clinical therapy, which are substrates of
the AcrB pump—tetracycline [29] and ciprofloxacin [30]. The combined effects of selenocompounds
and these antibiotics were tested on the AcrAB-TolC expressing Gram-negative E. coli AG100 strain.
In addition, the chemosensitizing effects of selenocompounds on the Gram-positive MRSA HEMSA 5
strain were studied in combination with oxacillin. These antibiotics have been selected among the
ones that are more widely used in clinical practice, in an attempt to cover different mechanisms of
action, to see which ones are more affected by the selenocompounds. Gram-negative efflux pumps of
the RND superfamily in Gram-negative bacteria are crucial to the cellular defence mechanisms, but the
overexpression of these pumps can lead to multidrug resistance, which is an alarming problem for
health care. The AcrAB-TolC system containing the RND type pump AcrB has been studied extensively,
due to its importance in bacterial resistance. As an in vitro model system we used the AcrAB-TolC
overexpressing E. coli AG100 strain and its pump-deleted mutant strain E. coli AG100A, in order to find
effective efflux pump inhibitor (EPI) compounds. EPIs as chemosenzitizers could reverse the resistant
phenotype, and in combination with antibiotics, they could enhance the activity of these conventional
antibiotics. Moreover, the Gram-positive methicillin resistant Staphylococcus aureus (MRSA) is a major
concern in healthcare facilities, for this reason our aim was to test the selenocompounds on reference
ATCC and resistant MRSA strains. The enhancement of the activity of oxacillin was studied as the
ability of compounds 1–11, to reduce MIC of oxacillin against MRSA, whereas the enhancement of
tetracycline or ciprofloxacin was studied analogously for AcrAB-TolC-expressing E. coli strain (Table 3).
In the absence of the selenocompounds, oxacillin showed MIC value of 374 µM (150 µg/mL)
against MRSA, since this strain was highly resistant to this β-lactam antibiotic. The methylketone
selenoester 9, at a low concentration of 1.95 µM (0.537 µg/mL), exerted a noteworthy 64-fold reduction
of the MIC value of oxacillin to 5.84 µM (2.34 µg/mL). Hence, this compound can be useful as a potent
agent to reverse the resistance of MRSA to oxacillin. Interestingly, the rest of the compounds 1–8, 10,
and 11 were not active, even at the concentration of 62.5 µM (MIC reduction of oxacillin ≤ 2).
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However, none of the tested selenocompounds were able to improve the efficacy of antibiotics
against the AcrAB-TolC-overexpressing strain of E. coli with the above-mentioned excellent 64-fold
factor. The highest reductions observed in E. coli were a 2-fold reduction of the MIC values of
tetracycline (compound 9) and of ciprofloxacin (compounds 9, 10).
Table 3. Numerical value of the reduction of the MICs of selected antibiotics in methicillin resistant
S. aureus (MRSA) or in E. coli AG100 exerted by selenocompounds when administered in combination
with antibiotics.
Cpd1
MRSA HEMSA 5 Escherichia coli AG100
Concentration of
Compound [µM]2
Reduction of
Oxacillin MIC
Concentration of
Compound [µM]
Reduction of
Tetracycline mic
Reduction of
Ciprofloxacin mic
1 62.5 no effect 50 no effect no effect
2 ND ND 3 50 no effect no effect
3 62.5 2-fold 50 no effect no effect
4 62.5 no effect 50 no effect no effect
5 62.5 no effect 50 no effect no effect
6 62.5 no effect 50 no effect no effect
7 62.5 ≥ 2-fold 50 no effect no effect
8 62.5 2-fold 50 no effect no effect
9 1.95 64-fold 25 2-fold 2-fold
10 62.5 no effect 50 no effect 2-fold
11 62.5 no effect 50 no effect no effect
1 Cpd: Compound. 2 Starting concentration of tetracycline: 8.4 µM; ciprofloxacin: 1.4 µM; and oxacillin: 747 µM.
3 ND: Not determined.
2.3. Anti-Chlamydial Activity
Before the assessment of the anti-chlamydial activity of the selenocompounds, a cytotoxicity assay
was performed on HeLa cells to determine the ranges of concentrations at which the selenocompounds
can be evaluated without showing direct toxic effects to HeLa cells. Selenocompounds 2, 3, 5, 7,
and 9–11, significantly inhibited the formation of chlamydial inclusions at selected concentrations
(Figure 1).Molecul s 2019, 24, x 6 of 14 
 
Figure 1. Anti-chlamydial effect of selenocompounds at 1.25 and 2.5 μM (A), and at 0.25 and 0.5 μM (B). 
Compounds 2 and 7 at 2.5 μM, showed 82% and 71% inhibition, compared to the control, 
respectively. In addition, 2 and 7 were effective at 1.25 μM, whereas 9 and 10 inhibited the formation 
of inclusions at low submicromolar concentrations of 0.5 μM. The most potent anti-chlamydial 
selenocompounds were 9 and 11, as they inhibited more than 50% of the growth of C. trachomatis D, 
at a concentration of 0.25 μM (0.0689 and 0.0858 μg/mL, respectively).  
2.4. Real-Time Accumulation Assay 
Since ethidium bromide (EB) is a substrate of the AcrB efflux pump, the intracellular 
accumulation of EB provides information about the inhibition of the AcrAB-TolC system, in the 
presence of selenocompounds, in a time-dependent manner. The assay records the real-time 
accumulation of EB, using a real-time thermocycler, by monitoring the fluorescence of EB inside the 
cells [31]. The activities of compounds 1–11 in the real-time EB accumulation assay, were given in 
terms of the relative fluorescence index (RFI) of the real-time accumulation curves (Table 4). In case 
of the real-time EB accumulation, the amount of EB accumulated by cells was higher if the difference 
between RFtreated and RFuntreated was greater, therefore, the degree of inhibition of the efflux pump 
system by the compound became greater. Compounds 9 and 10 possessed EPI activity and decreased 
the MIC of ciprofloxacin on E. coli AG100. However, the selenoanhydride 1 and the selenoester 4, 
compared with the positive control promethazine (PMZ, RFI: 0.15), strongly inhibited the efflux of 
AcrAB-TolC in E. coli AG100; they had no effect in combination with the antibiotics, suggesting that 
other cellular mechanisms might also be involved in the mode of action, such as interaction with cell 
wall components, formation of reactive oxygen species (ROS), or membrane destabilizing effects. 
Without investigating the possible metabolites of the selenocompounds, no further conclusions can 
be drawn, for this reason we are planning to study the metabolites of these compounds in future 
works. Derivatives 7 and 9–11 caused moderate inhibitory action, whereas 2, 3, 5, 6 and 8 showed 
weak or no activity on the intracellular EB accumulation in E. coli AG100. Among derivatives 7 and 
9–11, compound 7, which contained a methyl oxoester in the alkyl moiety bound to Se, was the most 
active agent (RFI = 0.13). 
Table 4. Relative fluorescence index (RFI) for the effect of selenocompounds and positive control 
promethazine (PMZ) on the AcrAB-TolC-expressing Escherichia coli AG100 strain.  
Compound 
RFIa 
Compound 
RFIa 
Compound 
RFIa 
Escherichia coli AG100  Escherichia coli AG100  Escherichia coli AG100  
1 0.28 5 0.04 9 0.11 
2 0.03 6 0.06 10 0.12 
3 0.04 7 0.13 11 0.11 
4 0.18 8 0.08 PMZ 0.15 
Figure 1. Anti-chlamydial effect of selenocompounds at 1.25 and 2.5 µM (A), and at 0.25 and 0.5 µM (B).
µ l,
. ff µ
µ
s ere 9 and 11, as they inhibited more than 50% of the growth of C. trachomatis D, at
concentration of 0.25 µM (0.0689 and 0.085 µg/mL, respectively).
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2.4. Real-Time Accumulation Assay
Since ethidium bromide (EB) is a substrate of the AcrB efflux pump, the intracellular accumulation
of EB provides information about the inhibition of the AcrAB-TolC system, in the presence of
selenocompounds, in a time-dependent manner. The assay records the real-time accumulation of EB,
using a real-time thermocycler, by monitoring the fluorescence of EB inside the cells [31]. The activities
of compounds 1–11 in the real-time EB accumulation assay, were given in terms of the relative
fluorescence index (RFI) of the real-time accumulation curves (Table 4). In case of the real-time EB
accumulation, the amount of EB accumulated by cells was higher if the difference between RFtreated and
RFuntreated was greater, therefore, the degree of inhibition of the efflux pump system by the compound
became greater. Compounds 9 and 10 possessed EPI activity and decreased the MIC of ciprofloxacin
on E. coli AG100. However, the selenoanhydride 1 and the selenoester 4, compared with the positive
control promethazine (PMZ, RFI: 0.15), strongly inhibited the efflux of AcrAB-TolC in E. coli AG100;
they had no effect in combination with the antibiotics, suggesting that other cellular mechanisms might
also be involved in the mode of action, such as interaction with cell wall components, formation of
reactive oxygen species (ROS), or membrane destabilizing effects. Without investigating the possible
metabolites of the selenocompounds, no further conclusions can be drawn, for this reason we are
planning to study the metabolites of these compounds in future works. Derivatives 7 and 9–11 caused
moderate inhibitory action, whereas 2, 3, 5, 6 and 8 showed weak or no activity on the intracellular EB
accumulation in E. coli AG100. Among derivatives 7 and 9–11, compound 7, which contained a methyl
oxoester in the alkyl moiety bound to Se, was the most active agent (RFI = 0.13).
Table 4. Relative fluorescence index (RFI) for the effect of selenocompounds and positive control
promethazine (PMZ) on the AcrAB-TolC-expressing Escherichia coli AG100 strain.
Compound
RFIa
Compound
RFIa
Compound
RFIa
Escherichia coli AG100 Escherichia coli AG100 Escherichia coli AG100
1 0.28 5 0.04 9 0.11
2 0.03 6 0.06 10 0.12
3 0.04 7 0.13 11 0.11
4 0.18 8 0.08 PMZ 0.15
Nevertheless, no efflux pump inhibitory action of selenocompounds (1–11) was found in the
E. coli AG100A strain.
2.5. Gene Expression Analysis by Quantitative PCR
For the effect of the selenocompounds on the relative expression of the efflux pump, antibiotic
resistance and QS genes inE. coliAG100—the most effective compounds in the EB real-time accumulation
assay—were examined (compounds 1, 4, 7; Figure 2). In this assay, the genes of the multidrug efflux
pump (AcrAB), the component of the E. coli mar locus (multiple antibiotic resistance), and the gene of
SdiA were investigated. The changes in gene expression from reverse transcription quantitative PCR
experiments were normalized to the expression of gapdh (internal control), in the same sample, and
compared to the expression of the examined genes obtained from the untreated, control samples.
As shown in Figure 2A, compound 1 at 50 µM concentration significantly up-regulated the acrB,
marR, and sdiA genes, after 4 h of exposure. However, after 18 h, the expression of the acrB gene
returned to the basal levels and the expression of the marR and sdiA genes, significantly increased.
Compound 4 up-regulated the expression levels of acrB, marR, and sdiA, after 4 h, although after
18 h, the expression levels of the acrB and marR genes decreased. The QS gene sdiA was significantly
up-regulated after 18 h (Figure 2B).
Compound 7 also significantly up-regulated marR, after exposures of 4 h and of 18 h. After 18 h,
the expression level of the RND transporters subunit genes (acrA, acrB) was significantly increased
(Figure 2C).
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3. Discussion
Results of these studies indicate that selenoesters and selenoanhydrides, previously found as
active anticancer or ABCB1 efflux pump inhibitors in cancer cells [7,8,32–35], also displayed a promising
antimicrobial potential against the MDR bacterial strains.
3.1. Antibacterial Activity
The evaluation of the compounds proved that the ketone-containing selenoesters 9–11 showed an
antibacterial activity against the Gram-positive reference S. aureus strain, whereas, the methylketone
selenoester 9 was also active against the MRSA HEMSA 5 and E. faecalis. However, none of the
compounds were active against the Gram-negative E. coli ag100. The background of the different
antibacterial activity of 9 against the tested Gram-positives and Gram-negatives was unknown;
further experiments are required to clarify whether the mechanism of action of the methylketone
selenoester could be related with any kind of interaction between this compound and the bacterial
cell wall that is typical for gram-positive bacteria. In contrast, the remaining alkyl groups (–CH3) or
alkyl-functionalized moieties (–CH2CON 2, –CH2COOCH3 and –CH2COOPh, Table 1) bound to
the Se at m rendered sel o sters that were ineffective against the tested strains. Interestingly, the
compounds 9–11 were also the most potent anticancer agents in previous works [7,8,33], and they also
showed a good selectivity towards cancer cells, with respect to non-tumour cell lines, as they showed
selectivity indexes ranging from 8.4 to 14.4 [8].
In previous works, it was hypothesized that the possible mechanism of action of these compounds
could be the hydrolysis of the compound and the subsequent liberation of the ionic species of Se, which
could be responsible for the activity of the compounds [33]. In this case, this phenomenon enables us
to hypothesize that the CH3COCH2SeH, or its anionic form, are the chemical forms of Se that could be
behind the observed activities. The lack of activity of the non-ketone selenoesters, directs a special
attention to this –SeCH2COCH3 ketone-containing moiety.
3.2. Enhancement of the Activity of Antibiotics
The activity of 9 on the MDR clinical isolate (MRSA) was very promising, because compound 9
reduced the MIC of oxacillin in 64-fold (from 374 µM to 5.84 µM). These results supported the potential
applications of the methylketone selenoesters, such as antimicrobials, and the multidrug resistance
reversing agents. These results were in accordance with the activity shown by these compounds
as enhancers of the anticancer activity of chemotherapy drugs [35], suggesting that these selenium
derivatives have the ability to effectively interact with the resistance mechanisms developed by the
resistant bacterial strains and by the resistant cancer cells. This work intends to carry out a screening
of the potential applications of the selenocompounds, and in future works we will attempt to ascertain
the possible mechanisms of actions of the activities described herein, as this observed potential
enhancement of the activity of oxacillin exerted by compound 9 in an MRSA clinical isolate.
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3.3. Anti-Chlamydial Activity
Previous studies have reported that selected selenocompounds, such as certain selenocyanates,
selenoureas, and diselenides, showed antiproliferative activities against the intracellular forms of
Leishmania spp. [36,37]. Taking those results into account, this study provided a new line of evidence for
the action of selenoanhydride/selenoesters on an obligate intracellular chlamydial strain. In particular,
different selenoesters, such as 2, 3, 5, 7, and 9–11, have exerted a noteworthy activity against
C. trachomatis D. Furthermore, the activities of the methyl (9) and the tert-butyl (11) derivatives were
very promising, as they inhibited the formation of more than 50% of the chlamydial inclusions, at a
very low concentration (0.25 µM). However, their mode of action has not been ascertained in this study.
Regarding the observed structure activity relationships of the anti-chlamydial assays, the ketone
selenoesters 9–11 showed noteworthy activity at lower concentrations (0.25 µM, 0.5 µM), compared to
the rest of the series (1.25 µM, 2.5 µM). Among the remaining selenoesters, the symmetric dimethyl
selenodiester, which contains a thiophene ring 2, and the methyl oxoester derivative 7 showed a better
activity, and the activities of the symmetric dimethyl selenodiesters 3 and 5 were also remarkable.
These fact highlights the importance of the symmetry for the activity against intracellular pathogens [36].
3.4. Interaction of the Compounds with Bacterial Efflux Pumps
The resistance to the current antibacterial drugs is one of the major therapeutic challenges in the
treatment of bacterial infections, and knowing the potential of these derivatives as multidrug resistance
reversing agents (proved both by the capacity to enhance the activity of antibiotics described above
and by the enhancement of anticancer drugs reported in previous works), we have studied here the
procedure through which selenocompounds interact with the bacterial AcrAB-TolC system in the E. coli
AG100 strain.
The results obtained revealed that the cyclic selenoanhydride 1 significantly inhibited this bacterial
AcrAB-TolC efflux pump in the E. coli AG100 strain. Similarly, EP inhibiting activity has been found
for compounds 4 and 7. The second most potent inhibitor was the symmetrical benzene derivative
1,3-disubstituted with methylselenoester moieties (4). Interestingly, its 1,4-disubstituted analogue
(5) showed an EP-inhibitory activity, 4.5-fold lower, suggesting the importance of the substituents’
topology for the expected biological effect. Taking into account the distinct difference in electron
density properties between m- and p-substituted phenyl rings, this factor seems to have affected the
mechanisms of EP inhibition.
The well-characterized RND-type transporter, AcrB is associated with TolC and AcrA and is
the major efflux pump of E. coli [38]. These efflux pumps recognize and extrude a large variety of
antibiotics from the cytoplasm. The energy required for the operation of the efflux pump is provided
by the proton motive force, created by the proton gradient resulting from electron transport [39].
This fact suggests that those selenocompounds, which possessed EP inhibitor activity, might interfere
with the proton motive force. Surprisingly, compounds 1 and 4, which inhibited the AcrAB-TolC
system, influenced the expression of the gene acrB, which is a constituent of the AcrAB-TolC system.
In addition, the compounds increased the expression of the QS gene sdiA, after 18 h of exposure, which
suggests their roles in QS, although their QS inhibitory activities were not investigated in this study.
4. Materials and Methods
4.1. Chemistry
Eleven pure selenocompounds obtained as described earlier [33], were examined (1–11, Table 1).
All compounds were stable in air and their purity was assessed by elemental analysis and 1H and
13C NMR, as reported in a previous work [35]. Before their use in biological assays, they were
dissolved in dimethyl sulfoxide (DMSO; Merck KGaA, Darmstadt, Germany), to obtain stock solutions.
Working solutions were prepared by dilutions in the culture medium.
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4.2. Bacterial Strains
Wild-type E. coli K-12 AG100 strain [argE3 thi-1 rpsL xyl mtl ∆(gal-uvrB) supE44] and its
AcrAB-TolC-deleted mutant strain E. coli AG100A (a kind gift from Hiroshi Nikaido, Department of
Molecular and Cell Biology and Chemistry, University of California, Berkeley, USA) were used for the
evaluation of the EPI activity of the tested selenocompounds.
S. aureus ATCC 25923 and E. faecalis ATCC 29212 strains were used to determine the MIC.
A methicillin-resistant S. aureus strain (MRSA HEMSA 5, a clinical isolate) was used in the combination
assay, with oxacillin, to determine the capacity of compounds to enhance the antibacterial effect of
this antibiotic. C. trachomatis reference strain (serovar D, UW-3/Cx, ATCC, VR-885D) was used in the
anti-chlamydial assay.
4.3. Propagation of C. trachomatis D
C. trachomatis D was propagated on the HeLa 229 cells (ATCC, CCL-2.1), as described earlier [40].
The titre of the infectious elementary bodies was determined by an indirect immunofluorescence assay.
Serial dilutions of the elementary bodies’ preparation were inoculated onto the HeLa monolayers and,
after a 48-h culture, the cells were fixed with acetone, and stained with monoclonal anti-Chlamydia LPS
antibody (AbD Serotec, Oxford, UK) and FITC-labelled anti-mouse IgG (Merck KGaA, Darmstadt,
Germany). The inclusions of C. trachomatis D were enumerated under a UV microscope.
4.4. Determination of MIC
The effects exerted by different concentrations of the compounds on the bacterial growth in
S. aureus, E. faecalis, and E. coli AG100 were tested in 96-well plates. The MICs of selenocompounds
were determined, according to the Clinical and Laboratory Standard Institute (CLSI) guidelines [41].
The DMSO exerted no antibacterial effect. Alternatively, the MIC of the oxacillin in MRSA HEMSA
5 was determined by the broth microdilution method, in a cation-adjusted Mueller–Hinton Broth
(MHB II), according to the recommendations of the CLSI. Results were recorded after a 20- or 24-hour
incubation at 37 ◦C.
4.5. Enhancement of the Activity of Antibiotics
The chemosensitizing effect of the tested selenocompounds was evaluated through the
determination of the MIC values of the antibiotics, in the presence of sub-inhibitory concentrations of
the compounds (MIC/2 or MIC/4), in both Gram-negative (E. coli AG100) and Gram-positive (MRSA)
strains. The MICs were evaluated in the E. coli strain, by a two-fold broth microdilution method in the
96-well plates, using serial dilutions of tetracycline (from 8.4 to 0.16 µM) and ciprofloxacin (from 1.4 to
2.7 × 10−3 µM). The first four rows contained two-fold dilutions of antibiotics, and the combinations of
the antibiotics and tested compounds were added into the last four rows. 10−4 dilution of an overnight
bacterial culture in 50 µL of MHB was then added to each well, with the exception of the medium
control wells. The plates were then incubated at 37 ◦C for 18 h. MIC values of the antibiotics and their
combination with the tested compounds were determined by naked eyes. In the assay with oxacillin in
the MRSA HEMSA 5 bacterial strain, a microdilution method in MHB II was used.
4.6. Anti-Chlamydial Assay
Elementary bodies ofC. trachomatisD (4× 103 IFU/mL) were incubated with compounds at selected
concentrations (0.25, 0.5, 1.25, 2.5 µM) in sucrose-phosphate-glutamic acid buffer (SPG) for 2 h at 37 ◦C.
As a control, C. trachomatis D was also incubated alone in the SPG. To quantify the anti-chlamydial
effects of the compounds, HeLa cells were seeded in 24-well plates with 13-mm cover glasses. The
confluent cells were infected with compound-treated C. trachomatis D or with the non-treated controls.
After 48 h, the cells were fixed with acetone at −20 ◦C for 10 min. The titre of the infectious elementary
bodies was determined by the indirect immunofluorescence assay, as described earlier [42].
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4.7. Real-Time Accumulation Assay
The effect of the studied selenocompounds on the real-time accumulation of ethidium bromide
(EB) was assessed by an automated EB method [43], using a LightCycler real-time thermocycler
(LightCycler 1.5; Roche). The compounds were added individually at different concentrations at MIC/2
to the EB solution in PBS. The final concentration of EB was 1 and 0.25 µg/mL for E. coli AG100 and
AG100A, respectively. The method for the calculation of the relative fluorescence index (RFI) of the last
time point (minute 30) was described earlier by Kincses et al. [44]. Promethazine (PMZ; EGIS) was
applied as a positive control.
4.8. Expression Analyses of Genes by Quantitative PCR
Total RNA was isolated from E. coli AG100 (OD of 0.6 at 600 nm) using the NucleoSpin RNA kit
(Macherey Nagel) according to the manufacturer’s instructions. The concentration of the extracted
RNA templates was assessed by spectrophotometry at 260 nm.
The expression of the acrA, the acrB, the multiple antibiotic resistance protein R (marR), and the
quorum-sensing transcriptional activator (sdiA) genes was studied by reverse transcription quantitative
PCR (RT-qPCR), as described earlier [44]. The real-time one-step PCR was performed in a CFX96 Touch
real-time PCR detection system (Bio-Rad), strictly adhering to the manufacturer recommendations of
the SensiFAST™ SYBR No-ROX One-Step Kit (Bioline GmbH, Luckenwalde, Germany). The forward
and reverse primers used in the experiment are shown in Table 5 [44,45]. The cycle threshold (Ct)
values were determined with the Bio-Rad CFX Manager Software version 3.1. Relative quantification
analysis was carried out using the Livak method [46]. The expression of gapdh was used as the internal
control and the untreated E. coli AG 100 served as the external control. We have defined a threshold
value—increases greater than 2-fold in the amount of transcripts relative to the control samples were
considered significant.
Table 5. Primers used in the RT-qPCR.
Gene Full Name Primer Sequence (5’–3’) Ampliconsize (bp) Ref.
acrA Acridine resistance protein A CTTAGCCCTAACAGGATGTGTTGAAATTACGCTTCAGGAT 189 [45]
acrB Acridine resistance protein B CGTACACAGAAAGTGCTCAACGCTTCAACTTTGTTTTCTT 183 [45]
marR Multiple antibiotic resistanceprotein R
AGCGATCTGTTCAATGAAAT
TTCAGTTCAACCGGAGTAAT 170 [45]
sdiA Quorum-sensingtranscriptional activator
CTGATGGCTCTGATGCGTTTA
TCTGGTGGAAATTGACCGTATT 163 [44]
gapdh Glyceraldehyde-3-phospatedehydrogenase
ACTTACGAGCAGATCAAAGC
AGTTTCACGAAGTTGTCGTT 170 [45]
5. Conclusions
Herein, we have reported the evaluation of the antibacterial and multidrug resistance reversing
activity of 11 novel selenocompounds. The most active compound in the antibacterial assay, the
methylketone selenoester 9, showed potential antibacterial activity against the different strains of
S. aureus, E. faecalis, and C. trachomatis D, even at very low concentrations (0.25 µM for C. trachomatis
D). This selenocompound also enhanced the efficacy of antibiotics, namely it multiplied by 64-fold
the antibacterial action of oxacillin, against the MDR clinical isolate of S. aureus. Alternatively, three
compounds (the selenoanhydride 1 and the selenoesters 4 and 7) inhibited the tripartite multidrug
resistance efflux pump AcrAB-TolC in E. coli, and affected the expression of the different genes related
to these resistance processes.
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Based on these results, it can be concluded that this group of selenocompounds can be attractive
potential EP inhibitors and antibacterial lead scaffolds, for further development of new chemical tools,
to overcome bacterial multidrug resistance.
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